Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Eastern Cooperative Oncology Group
Insel Gruppe AG, University Hospital Bern
Centre Leon Berard
Fudan University
Covenant Health Cancer Center
Groupe Oncologie Radiotherapie Tete et Cou
University of Chicago
Gustave Roussy, Cancer Campus, Grand Paris
Radboud University Medical Center
Radiation Therapy Oncology Group
Tehran University of Medical Sciences
Tata Memorial Hospital
Groupe Oncologie Radiotherapie Tete et Cou
All India Institute of Medical Sciences
Tehran University of Medical Sciences